Lantern Pharma CEO Panna Sharma Remains in Position, Addresses False Claims
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy LTRN?
Source: Newsfilter
- Executive Stability: Lantern Pharma emphasizes that Panna Sharma remains as President and CEO, refuting false claims of his resignation, thereby ensuring investor confidence in the company's leadership.
- Clinical Pipeline Progress: Under Sharma's leadership, Lantern is advancing its clinical pipeline, including the recently cleared IND for STAR-001 targeting pediatric CNS cancer, demonstrating the company's proactive stance in oncology drug development.
- Legal Action Plan: Lantern is investigating the origin of the false article and considering legal remedies to protect the company and its shareholders from misleading information, showcasing its commitment to market integrity.
- Financial Performance Release: Lantern will host a webcast on March 30, 2026, to discuss Q4 and fiscal year 2025 operating and financial results, further enhancing transparency and providing investors with the latest updates.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy LTRN?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on LTRN
Wall Street analysts forecast LTRN stock price to rise
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 2.090
Low
25.00
Averages
25.00
High
25.00
Current: 2.090
Low
25.00
Averages
25.00
High
25.00
About LTRN
Lantern Pharma Inc. is an artificial intelligence (AI) company. The Company is developing cancer therapies and transforming the cost, pace, and timeline of oncology drug discovery and development. Its proprietary AI and machine learning (ML) platform, RADR, leverages over 100 billion oncology-focused data points and a library of over 200+ advanced ML algorithms to help solve problems in oncology drug development. It is engaged in the development of its pipeline of therapies that span multiple cancer indications, including both solid tumors and blood cancers and an antibody drug conjugate (ADC) program. It has active clinical programs for its three lead small molecule drug candidates: LP-300, LP-184, and LP-284. These programs are focused on multiple cancer indications, including both solid tumors and blood cancers. It is also focused on the clinical execution of its therapies for CNS and brain cancers through Starlight Therapeutics Inc.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
LANTERN PHARMA STOCK RISES 7.1% FOLLOWING FDA APPROVAL FOR CHILD BRAIN CANCER TREATMENT TRIAL
- Company Performance: Lantheus Holdings reported a 7.1% increase in shares following the announcement of receiving FDA clearance.
- New Treatment Study: The FDA clearance allows Lantheus to start a study on treatments for childhood brain cancer.
See More
Lantern Pharma CEO Panna Sharma Remains in Position, Addresses False Claims
- Executive Stability: Lantern Pharma emphasizes that Panna Sharma remains as President and CEO, refuting false claims of his resignation, thereby ensuring investor confidence in the company's leadership.
- Clinical Pipeline Progress: Under Sharma's leadership, Lantern is advancing its clinical pipeline, including the recently cleared IND for STAR-001 targeting pediatric CNS cancer, demonstrating the company's proactive stance in oncology drug development.
- Legal Action Plan: Lantern is investigating the origin of the false article and considering legal remedies to protect the company and its shareholders from misleading information, showcasing its commitment to market integrity.
- Financial Performance Release: Lantern will host a webcast on March 30, 2026, to discuss Q4 and fiscal year 2025 operating and financial results, further enhancing transparency and providing investors with the latest updates.
See More
LANTERN PHARMA AFFIRMS PANNA SHARMA REMAINS PRESIDENT AND CEO; WARNS INVESTORS ABOUT INACCURATE THIRD-PARTY REPORT
Company Leadership: Lanterra Pharma confirms that its President and CEO, Aleksey Sharman, will continue in his role.
Investor Alert: The company has issued a warning to investors regarding a false third-party report that may mislead stakeholders.
See More
Lantern Pharma Receives FDA Clearance for STAR-001 Pediatric Trial
- Stock Decline: Lantern Pharma Inc.'s stock is down approximately 10% in Friday morning trading, currently priced at $1.88, reflecting a 10.04% drop from the previous close of $2.09, indicating negative market sentiment regarding the clinical trial announcement.
- FDA Trial Approval: The company, along with its subsidiary Starlight Therapeutics, announced that the U.S. Food and Drug Administration has cleared the Investigational New Drug application for STAR-001, marking a significant step forward in its drug development efforts.
- Clinical Trial Design: The planned trial will evaluate STAR-001 both as a single agent and in combination with spironolactone in pediatric patients with relapsed or refractory central nervous system malignancies, aiming to provide new treatment options for this high-risk population.
- Market Volatility: Over the past year, Lantern Pharma's stock has fluctuated between $1.82 and $5.7440, and the current decline may impact investor confidence and exert pressure on the company's future financing and research plans.
See More
Lantern Pharma Receives FDA IND Approval for STAR-001
- Stock Surge: Lantern Pharma Inc. (LTRN) shares surged nearly 18% in pre-market trading on Friday, reflecting strong market optimism regarding its drug development and investor confidence in the company's future potential.
- FDA IND Approval: The U.S. Food and Drug Administration (FDA) has cleared Lantern's Investigational New Drug (IND) application for STAR-001, enabling the company to initiate a Phase 1 pediatric clinical trial for central nervous system cancers, marking a significant milestone in its research progress.
- Precision Oncology Innovation: STAR-001 is a precision oncology compound discovered using Lantern's proprietary RADR AI platform, indicating the company's leadership in leveraging artificial intelligence for drug discovery, potentially offering new hope for pediatric cancer treatment.
- Clinical Trial Collaboration: The trial will be conducted in collaboration with the Pediatric Oncology Experimental Therapeutics Investigators' Consortium, evaluating STAR-001 both as a standalone treatment and in combination with Spironolactone, showcasing the company's strategic positioning in the pediatric oncology space.
See More
FDA Approves STAR-001 for Pediatric CNS Cancer Trial
- FDA IND Approval: Lantern Pharma and its subsidiary Starlight Therapeutics announced that the FDA has cleared the IND application for STAR-001, marking a significant advancement in pediatric neuro-oncology with plans for a Phase 1 trial in children with relapsed or refractory CNS tumors.
- Trial Design: The trial will evaluate STAR-001 both as a monotherapy and in combination with spironolactone, aiming to enroll 18 to 42 pediatric patients aged 1 to 17 years across 14 leading academic children's cancer centers in the U.S., Canada, and Israel, addressing a critical gap in pediatric oncology treatment options.
- Targeting Key Biomarker: STAR-001 targets the ERCC3 DNA repair enzyme, and when combined with spironolactone, aims to induce DNA double-strand breaks that enhance tumor cell death; preclinical data shows this combination extended median survival by 181% in ATRT models, indicating significant therapeutic potential.
- Global Pediatric Cancer Landscape: An estimated 4,975 new cases of pediatric brain tumors are expected in the U.S. by 2026, making brain tumors the leading cause of cancer-related deaths among children aged 0 to 19, with approximately 47,600 new pediatric CNS tumor cases diagnosed globally each year, highlighting the urgent need for new therapies.
See More
LANTERN PHARMA STOCK RISES 7.1% FOLLOWING FDA APPROVAL FOR CHILD BRAIN CANCER TREATMENT TRIAL
- Company Performance: Lantheus Holdings reported a 7.1% increase in shares following the announcement of receiving FDA clearance.
- New Treatment Study: The FDA clearance allows Lantheus to start a study on treatments for childhood brain cancer.
See More
Lantern Pharma CEO Panna Sharma Remains in Position, Addresses False Claims
- Executive Stability: Lantern Pharma emphasizes that Panna Sharma remains as President and CEO, refuting false claims of his resignation, thereby ensuring investor confidence in the company's leadership.
- Clinical Pipeline Progress: Under Sharma's leadership, Lantern is advancing its clinical pipeline, including the recently cleared IND for STAR-001 targeting pediatric CNS cancer, demonstrating the company's proactive stance in oncology drug development.
- Legal Action Plan: Lantern is investigating the origin of the false article and considering legal remedies to protect the company and its shareholders from misleading information, showcasing its commitment to market integrity.
- Financial Performance Release: Lantern will host a webcast on March 30, 2026, to discuss Q4 and fiscal year 2025 operating and financial results, further enhancing transparency and providing investors with the latest updates.
See More
LANTERN PHARMA AFFIRMS PANNA SHARMA REMAINS PRESIDENT AND CEO; WARNS INVESTORS ABOUT INACCURATE THIRD-PARTY REPORT
Company Leadership: Lanterra Pharma confirms that its President and CEO, Aleksey Sharman, will continue in his role.
Investor Alert: The company has issued a warning to investors regarding a false third-party report that may mislead stakeholders.
See More
Lantern Pharma Receives FDA Clearance for STAR-001 Pediatric Trial
- Stock Decline: Lantern Pharma Inc.'s stock is down approximately 10% in Friday morning trading, currently priced at $1.88, reflecting a 10.04% drop from the previous close of $2.09, indicating negative market sentiment regarding the clinical trial announcement.
- FDA Trial Approval: The company, along with its subsidiary Starlight Therapeutics, announced that the U.S. Food and Drug Administration has cleared the Investigational New Drug application for STAR-001, marking a significant step forward in its drug development efforts.
- Clinical Trial Design: The planned trial will evaluate STAR-001 both as a single agent and in combination with spironolactone in pediatric patients with relapsed or refractory central nervous system malignancies, aiming to provide new treatment options for this high-risk population.
- Market Volatility: Over the past year, Lantern Pharma's stock has fluctuated between $1.82 and $5.7440, and the current decline may impact investor confidence and exert pressure on the company's future financing and research plans.
See More
Lantern Pharma Receives FDA IND Approval for STAR-001
- Stock Surge: Lantern Pharma Inc. (LTRN) shares surged nearly 18% in pre-market trading on Friday, reflecting strong market optimism regarding its drug development and investor confidence in the company's future potential.
- FDA IND Approval: The U.S. Food and Drug Administration (FDA) has cleared Lantern's Investigational New Drug (IND) application for STAR-001, enabling the company to initiate a Phase 1 pediatric clinical trial for central nervous system cancers, marking a significant milestone in its research progress.
- Precision Oncology Innovation: STAR-001 is a precision oncology compound discovered using Lantern's proprietary RADR AI platform, indicating the company's leadership in leveraging artificial intelligence for drug discovery, potentially offering new hope for pediatric cancer treatment.
- Clinical Trial Collaboration: The trial will be conducted in collaboration with the Pediatric Oncology Experimental Therapeutics Investigators' Consortium, evaluating STAR-001 both as a standalone treatment and in combination with Spironolactone, showcasing the company's strategic positioning in the pediatric oncology space.
See More
FDA Approves STAR-001 for Pediatric CNS Cancer Trial
- FDA IND Approval: Lantern Pharma and its subsidiary Starlight Therapeutics announced that the FDA has cleared the IND application for STAR-001, marking a significant advancement in pediatric neuro-oncology with plans for a Phase 1 trial in children with relapsed or refractory CNS tumors.
- Trial Design: The trial will evaluate STAR-001 both as a monotherapy and in combination with spironolactone, aiming to enroll 18 to 42 pediatric patients aged 1 to 17 years across 14 leading academic children's cancer centers in the U.S., Canada, and Israel, addressing a critical gap in pediatric oncology treatment options.
- Targeting Key Biomarker: STAR-001 targets the ERCC3 DNA repair enzyme, and when combined with spironolactone, aims to induce DNA double-strand breaks that enhance tumor cell death; preclinical data shows this combination extended median survival by 181% in ATRT models, indicating significant therapeutic potential.
- Global Pediatric Cancer Landscape: An estimated 4,975 new cases of pediatric brain tumors are expected in the U.S. by 2026, making brain tumors the leading cause of cancer-related deaths among children aged 0 to 19, with approximately 47,600 new pediatric CNS tumor cases diagnosed globally each year, highlighting the urgent need for new therapies.
See More
